The Effect of Brahmi Nei With Massage And Varmam on Spasticity of Cerebral Palsy Children

Arul Mozhi P
Lecturer, National Institute of Siddha, Chennai, Tamil Nadu

Pattaryan R
Professor (Rtd), National Institute of Siddha, Chennai, Tamil Nadu

Deivanayagi.S
Asst.Professor, Sri Sairam Institute of Technology, Chennai, Tamil Nadu

ABSTRACT

The Objective of the study is to determine the effect of Brahmi Nei with massage and varmam on spasticity of children with spastic cerebral palsy. Among the 250 children 210 Spastic CP satisfied the inclusion criteria and were divided in to three groups (N=70 Nos). Group –I treated as an active control, Group –II received Brahmi Nei, Group - III received Brahmi Nei along with external therapies such as massage with Vasavu ennai and Varmam twice a day. Experimental period was 90 days and spasticity was recorded 0th day and followed by every 30th day. Group III had decreased spasticity in different group of muscles which are compared with other two groups. Finally, it can be concluded that Brahmi Nei along with Vasavu ennai massage and Varmam has a clinical efficacy on spasticity in cerebral palsy children.

KEYWORDS : Cerebral palsy, Brahmi Nei, Vasavu ennai, Spaticity

1. Introduction

Cerebral palsy (CP) is described as “a group of disorders of the movement and posture, that are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of spasticity and rigidity.” The prevalence of cerebral palsy is estimated to be 1.5-3 per 1000 live births, with variations possibly differences in ascertainment and classification 12. During the last years, focus of care for children with cerebral palsy has shifted from a main emphasis on motor function, towards participation and minimizing limitations of activity, in line with the World Health Organization (WHO) framework; the International Classification of Functioning, Disability and Health (ICF). Throughout the years a large number of treatment options have been available for spasticity children with cerebral palsy. Today the ultimate aim with therapy is to promote activity and participation in everyday life according to the child’s and family’s priorities.

Clinical outcomes include improvement of spasticity and the ability to participate in daily activities. Oral Baclofen, Tizanidine, Dantrolene, Diazepam and Gabapentin are widely used for spasticity. Not all children with spasticity benefit from this treatment14, the incidence of adverse drug effects (drowsiness, sedation and muscle weakness) were high. Children with localized or multifocal spasticity injections have benefit of Botulinum toxins15 formation of antibodies against has been demonstrated16. Neurosurgery such as rhizotomy and orthopaedic surgery (tendon lengthening and soft tissue releases) may be the options17. In view of all of the above, an immediate and urgent need exists to look for an alternative form of therapy such as natural products. In India, Siddha system of medicine owes its origin to medicinal ideas and practices of a class of Tamil sages. It has bio pharma products such as herbs, minerals, metals and salts all have been used for pediatric population. The purpose of this research work is to develop recommendations on “best practices” related primarily to the evaluate Siddha methodologies and Medicines. Different treatment modalities can improve the quality of life to the disabled children and these can include Siddha bio pharma products included Brahmi Nei18 as internal medicine, Vasavu ennai19 for thokkanam (Massage) and Varama therapy20 as external, all of which have been used in the Siddha system of medicine for many centuries either singly or in various combination. In order to limit this issue, efforts were undertaken to study the result of the use of a combination of these therapy.

2. Materials and Methods

2.1 Preparation of Experimental Formulations

Brahmi Nei as internal medicine and Vasavu ennai for thokkanam (Massage) were identified for this study. Raw drugs to prepare the products were purchased from the market and fresh plants were collected from wild sources. The raw materials have got authentication from Department of Medicinal Botany, National Institute of Siddha, and Chennai.

Brahmi Nei
Brahmi Nei was prepared as described as in the sasrith Siddha literature. Briefly, it was prepared by adding paste of Zingiber officinale Linn., (Dried Rhizome) Piper longum Linn. (Dry fruit), Alpenia officinarum Linn. (Dried Rhizome), Feronia elephantum Linn.(seed), Induppu, Caryota urens Linn.(pal jaggery), Gurkura aromatic Linn.(Rhizome) each 14gms, in freshly prepared Bacopa monniera Linn.(5.44kg), Acorus calamus Linn.(1.36 kg), Alpenia galanga Linn. (1.36kg), and in vessel having Cow’s milk (5.4kg), Cow’s Ghee,(2.72 kg). Above mixture was heated and filtered after acquiring completion test and boiled in medium flame with continuous stirring and monitoring of paakam. The boiling was stopped and the oil was filtered using a washed and dried white filter cloth when chikku patham was attained. In this way, Birami Nei was prepared.

Vasavu Ennai
Vasavu ennai was also prepared as described also in the sasrith Siddha literature. Briefly, it was prepared by adding paste of Hernandesmus indicus Linn.(100gms), in freshly prepared juice of Citrus auranti-folia Linn., Aloe barbadensis Linn., in vessel having Cocos nucifera Linn oil and Ricinus communis Linn., oil each one litre. Above mixture was heated and filtered after acquiring completion test and boiled in medium flame with continuous stirring and monitoring of paakam. The boiling was stopped and the oil was filtered using a washed and dried white filter cloth when chikku patham was attained. In this way, Vasavu Ennai was prepared.

2.2 Clinical Study

The present study was a prospective, open label, non-randomized, outpatient and inpatient based, single centered drug trial conducted in the department of Kuzhanthai Maruthuvam (Pediatric), National institute of Siddha, Chennai. It was conducted during 2011 to December 2016 after obtaining approval from the Institute Ethics Committee (NIS/IEC/2011/3/48). Single batch of Brahmi Nei and Vasavu ennai were prepared for the entire study. The first 250 children with spastic cerebral palsy were screened during the study period. Children of either sex between the age group of 3 to 12yrs, who were diagnosed with spastic cerebral palsy, were identified to include the study. Other type of cerebral palsies and along with seizure disorder, Spinal deformities, impaired vision Autistic Spectrum Disorders, ADD/ADHD (Hyper activity), Mental Retardation, Visual Impairments and Blindness, Hearing Loss and Deafness, Down Syndrome, Spina Bifida, Traumatic Brain Injury were excluded from the study. 210 children satisfied the inclusion criteria and were willing to participate in the study, signed the informed consent. The parents of children who were enrolled was informed about the study, trial drug, possible outcomes and the objectives of the study in the language and terms understandable for them.

Children were divided in to three groups (N=70 Nos). Group –I treated as an active control received regular OPD medicines, Group –II received internal medicine Brahmi Nei (3 yrs to 5 yrs - 8 ml, 6 yrs to 9
yrs - 10 ml, 10 yrs to 12 yrs - 12 ml) twice a day. Group - III received internal medicine Brahmi Neel along with external therapies such as massage with Vasavu ennai and Varmam (Kondai kolli, Natchathira kaalam, Thilarthra varmam, Pidari kaalam) twice a day. Experimental period was 90 days and spasticity was recorded 0th day and followed by every 30th day. Experimental formulations were assigned to each subject and regular study drug reconciliation was performed to document the drug assigned, consumed, and remaining are logged on the drug reconciliation form with sign & date.

2.3 Assessment of Spasticity
The most commonly used definition of spasticity is described by Lance (1980) i.e “Spasticity is a motor disorder characterized by a velocity-dependent increase in tonic stretch reflexes (muscle tone) with exaggerated tendon jerks, resulting from hyper excitability of the stretch reflex, as one component of the upper motor neuron syndrome”. Several methods have been developed and used to assess spasticity. The most commonly used test in clinical practice is the MAS - B12. The test is based on the assessment of resistance to passive stretch of muscle group at one non specified velocity in Gastrocnemous and Soleus, Hip adductors, Thigh flexors and extensors, Triceps and biceps, Shoulder girdle and trunk muscles, Forearm flexors and extensors.

0 - No increase in muscle tone
1 - Slight increase in muscle tone, manifested by a catch and release by minimal resistance throughout the remainder (less than half) of the ROM
1+ - Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM
2 - More marked increase in muscle tone through most of the ROM, affected part(s) easily moved
3 - Considerable increase in muscle tone, passive movement difficult
4 - Affected part(s) rigid in flexion or extension

2.4 Statistical Analysis
All of the analyses were performed using the SPSS statistical software, version 20.0. The results are expressed as mean ± SD. Statistical significance was tested by means of analysis of variance (ANOVA), paired students t-test for within-group comparison and the independent student t-test was used for comparisons between the two therapy groups and the group means were compared by Duncan’s Multiple Range Test (DMRT). Values were considered statistically significant when at p < 0.05.

3. Results and Discussion
Table 1. Spasticity changes Gastrocnemous and Soleus, Hip adductors, Thigh flexors and extensors muscles

<table>
<thead>
<tr>
<th>Days</th>
<th>Gastrocnemous and Soleus</th>
<th>Hip adductors</th>
<th>Thigh flexors and extensors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 0</td>
<td>Mean ± SD</td>
<td></td>
<td>Mean ± SD</td>
</tr>
<tr>
<td></td>
<td>3.59 ± 1.03</td>
<td>3.69 ± 1.08</td>
<td>3.60 ± 1.03</td>
</tr>
<tr>
<td>Day 30</td>
<td>3.51 ± 0.88</td>
<td>3.50 ± 0.94</td>
<td>3.21 ± 0.95</td>
</tr>
<tr>
<td>Day 60</td>
<td>3.43 ± 1.06</td>
<td>3.50 ± 1.11</td>
<td>3.10 ± 0.96</td>
</tr>
<tr>
<td>Day 90</td>
<td>3.39 ± 0.74</td>
<td>3.39 ± 1.13</td>
<td>2.64 ± 0.93</td>
</tr>
</tbody>
</table>

Table 2. Spasticity changes Triceps and biceps, Shoulder girdle and trunk muscles, Forearm flexors and extensors muscles

<table>
<thead>
<tr>
<th>Days</th>
<th>Triceps and biceps</th>
<th>Shoulder girdle and trunk muscles</th>
<th>Forearm flexors and extensors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 0</td>
<td>Mean ± SD</td>
<td>Mean ± SD</td>
<td>Mean ± SD</td>
</tr>
<tr>
<td></td>
<td>3.84 ± 0.88</td>
<td>3.81 ± 0.95</td>
<td>3.81 ± 0.96</td>
</tr>
<tr>
<td>Day 30</td>
<td>3.79 ± 0.96</td>
<td>3.93 ± 0.89</td>
<td>3.89 ± 0.96</td>
</tr>
<tr>
<td>Day 60</td>
<td>3.57 ± 0.89</td>
<td>2.98 ± 0.91</td>
<td>3.90 ± 0.83</td>
</tr>
<tr>
<td>Day 90</td>
<td>3.49 ± 0.90</td>
<td>2.98 ± 0.91</td>
<td>3.79 ± 0.96</td>
</tr>
</tbody>
</table>

Spasticity changes in the different clinical groups at 90 days of treatment. The number of children in each group is given within parentheses. Values are given as mean ± S.D for 70 children in each group. Values not sharing a common superscript letter differ significantly at p < 0.05 (DMRT).

Fig.1. Spasticity changes Gastrocnemous and Soleus, Hip adductors

Fig.2 Spasticity changes Thigh flexors and extensors, Triceps and biceps muscles

Fig.3 Spasticity changes Shoulder girdle and trunk muscles, Forearm flexors and extensors

While the Group II of children showed no significant reduce in spasticity, children of Group I and Group III showed significant reduction in spasticity all group of muscles. However, there was no significant difference in spasticity changes in group II. This study indicating that the combined therapy of internal medicine and external medicine had superior action as far as reduction in spasticity is concerned. We observed that the single internal
References
7. Tamil Nadu Siddha Medical Board 1995, 116
8. Siddha Hospital Pharmacopeia Part-I